3Cohen MH, Williams GA, Sridhara R, et al. FDA drug ap- proval summary : gefitinib ( ZD1839 ) ( Iressa ) tablets [ J ]. Oncologist, 2003,8 (4) : 303 -306.
4Cataldo VD, Gibbons DL, Perez-Soler R, et al. Treatment of non-small cell lung cancer with erlotinib or gefitinib [ J ]. N Engl J Med, 2011,364(10) :947-955.
5Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med, 2010,362 (25) :2380-2388.
6Okamoto I, Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer[J]. Lung Cancer, 2003, 40 (3) :339-342.
7Shan NT, Kris MG, Pao W, et al. Practical management of patients with non small-cell lung cancer treated with gefitinib [J]. J Clin Oncol, 2005, 23(1) :165-174.
8Chang SC, Chang CY, Chang SJ, et al. Gefitinib-related in- terstitial lung disease in Taiwan Residents patients with non-small- cell lung cancer [ J ]. Clin Lung Cancer, 2013, 14 ( 1 ) : 55-61.
9Shi L, Tang J,Tong L, et al. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials[J]. Lung Cancer, 2014, 83(2) :231-239.
10Min JH, Lee HY, Lim H, et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non- small-cell lung cancer: a review on current insight [ J ]. Cancer Chemother Pharmacol, 2011, 68(5) :1099-1109.
